Navigation Links
Kinex Pharmaceuticals Receives Substantial Strategic Investment
Date:7/31/2012

BUFFALO, N.Y., July 31, 2012 /PRNewswire/ -- Kinex Pharmaceuticals, LLC announced today that it has received a substantial investment from a prominent Asian investor.

Dr. Manson Fok is the Founder of the Pedder Clinic, which is one of the largest private medical practices in Hong Kong. Dr. Fok is the Dean of the Faculty of Health Sciences at the University of Macau (MUST) and President of the Macau Healthcare Management and Promotion Association (MHMPA).

"Greater China is well prepared to evolve as a global player in the field of biotechnology and pharmaceuticals. I look forward to assisting Kinex Pharmaceuticals in their Asian business strategy," stated Dr. Fok.

"Dr. Fok is a very successful doctor, entrepreneur, and a philanthropist. We are delighted that he has agreed to serve the Company as an advisor.  His scientific knowledge, his business experience and his extensive network will be instrumental as Kinex advances its Asian strategy," stated Dr. Johnson Yiu-Nam Lau, Chairman and CEO of Kinex Pharmaceuticals.

"Securing the confidence of a strategic investor such as Dr. Manson Fok cannot be overstated," said Mr. Flint Besecker, Chairman of the Finance, Audit and Risk Management Committee of the Kinex Board of Directors. Mr. Besecker was formerly Managing Director of GE Healthcare Financial Services.

About Kinex Pharmaceuticals, LLC

Kinex Pharmaceuticals, headquartered in Buffalo, New York, USA, is using its proprietary technologies Mimetica™ and Opal™ to discover and develop novel drugs for oncology and immune-modulatory diseases. More information of Kinex Pharmaceuticals can be found at www.kinexpharma.com

Kinex Pharmaceuticals, LLC Caution Regarding Forward-looking Information

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Kinex Pharmaceuticals cautions investors that any forward-looking statements or projections made by Kinex Pharmaceuticals, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected.

Kinex Inquiries:

Lyn M. Dyster, Ph.D.
Senior VP, Operations
Kinex Pharmaceuticals
701 Ellicott Street
Buffalo, NY 14203
USA
E-mail: ldyster@kinexpharma.com


'/>"/>
SOURCE Kinex Pharmaceuticals, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... 2017 E.I. Medical Imaging (EIMI) has partnered ... custom design the worlds first ultrasound system to be used ... native habitat. In preparation for a piece produced by ... Week, Dr. Guttridge approached EIMI with the idea of an ... hammerhead sharks underwater. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 ... to treat rare nervous system diseases, has concluded a worldwide ... market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before this ... results in a Phase 2 study conducted in ... the United States ...
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 ... the University of Alberta in Edmonton, ... Nature,s partner journal, Schizophrenia 1 , demonstrating that ... of schizophrenia with 74% accuracy. This retrospective analysis ... specific symptoms in schizophrenia patients with significant correlation, ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... 26, 2017 , ... Evergreen Healthcare Partners is proud to ... to provide innovative offerings to their healthcare partners. These solutions will help Evergreen’s ... teams to address healthcare IT’s biggest challenges. , “Adding Talent Management Solutions to ...
(Date:7/26/2017)... ... July 26, 2017 , ... The ... Process Validation and Process Validation Statistics Conferences in Bethesda, Maryland, 12 – ... challenges faced by process validation professionals and statisticians today. , “These conferences ...
(Date:7/26/2017)... , ... July 26, 2017 , ... “We are thrilled ... the ability for patients to schedule an appointment online in real time,” said Keith ... Six Month Smiles provider directory will bring more Six Month Smiles patients to their ...
(Date:7/26/2017)... ... July 26, 2017 , ... The Amnesty Rally 2017 will be held on ... 3313 Bernstein Park Drive in Monroe (adjacent to the Louisiana Purchase Gardens & Zoo). ... gun violence throughout Monroe. Citizens can turn in unregistered, illegally-held and imitation guns to ...
(Date:7/25/2017)... ... , ... “Now Hiring!” is a popular phrase at Home Delivery Incontinent ... sales for over 30 consecutive years and now plans to hire more than 100 ... excitement and growth at HDIS, following the company’s acquisition by Fortune 1000 company Domtar. ...
Breaking Medicine News(10 mins):